<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635360</url>
  </required_header>
  <id_info>
    <org_study_id>18472</org_study_id>
    <secondary_id>UVA-LACC-PD201</secondary_id>
    <nct_id>NCT02635360</nct_id>
  </id_info>
  <brief_title>Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linda R Duska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in
      combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced
      cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will
      be administered after or during chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary: (1) To estimate the immunologic effects, as assessed in the tumor &amp; PBMC, of both
      sequential and concurrent administration of pembrolizumab to CRT. Change between pre and post
      measurements of HPV E2, E7 specific CD8+ T cells, regulatory FoxP3+ T cells (Tregs) and the
      ratio of CD8+ T cells to Tregs are the immune measurements of primary interest. (2) To
      determine the safety of concurrent chemoradiation in combination with pembrolizumab for the
      treatment of locally advanced cervical cancer. Secondary: (1) To estimate rates of complete
      metabolic response on PET/CT imaging obtained 12 weeks after CRT.

      (2) To estimate rates of distant metastasis as the first site of recurrence for patients.

      (3) To estimate the influence of concurrent and consolidative MK-3475 on levels of
      plasminogen activator inhibitor-1 (PAI-1), a marker of immunosuppressive TGF-B.

      (4) To estimate the influence of concurrent and consolidative MK-3475 on levels of IDO, an
      enzyme that depletes tryptophan, which is essential for T-cell function.

      (5) To estimate the influence of concurrent and consolidative MK-3475 on levels of MHC class
      I (CD8+ T cell ligand) and MICA (NK ligand), as measured by MHC.

      (6) To estimate the progression free survival (PFS) in subjects with locally advanced
      cervical cancer treated with sequential and concurrent administration of pembrolizumab in
      relation to CRT.

      (7) To estimate the overall survival (OS) in subjects with locally advanced cervical cancer
      treated with sequential and concurrent administration of pembrolizumab in relation to CRT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in immunologic markers following combination of study drug with chemoradiation</measure>
    <time_frame>At 6 weeks of chemoradiation and 12 weeks post-chemoradiation</time_frame>
    <description>Expression of immune markers measured at pre and post administration of study drug with chemoradiation will be compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities</measure>
    <time_frame>From start of treatment until 12 weeks post-chemoradiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic Response Rate on PET/CT imaging</measure>
    <time_frame>12 weeks after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of distant metastases</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From start of treatment until up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.</description>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>Radiation is done for standard clinical care purposes.</description>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <other_name>chemoradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg of chemotherapy drug will be given weekly for 5-6 weeks.</description>
    <arm_group_label>Concurrent to chemoradiation</arm_group_label>
    <arm_group_label>Following chemoradiation</arm_group_label>
    <other_name>chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed cervical cancer.

          -  Must have adequate organ function.

        Exclusion Criteria:

          -  Subject is pregnant.

          -  Recurrent cervical cancer.

          -  Distant metastases.

          -  Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of
             the skin that has undergone potentially curative therapy is permissable.

          -  Subject has had prior radiation, chemotherapy, targeted therapy, or investigational
             therapy for cervical cancer.

          -  Subject has a immunodeficiency.

          -  Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.

          -  Hypersensitivity to pembrolizumab or similar drugs.

          -  Subject has an active autoimmune disease in the past 2 years.

          -  Known history of non-infectious pneumonitis.

          -  Subject has an active infection.

          -  Subject has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases are permissible. Talk to
             Study Contact for specifics.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Duska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April M Muniz, MSHS</last_name>
    <phone>434-243-5350</phone>
    <email>am4pf@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Duska</last_name>
    <email>lduska@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanie Broemmelsiek</last_name>
      <phone>251-445-9866</phone>
      <email>jbroemmelsiek@health.southalabama.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Russell</last_name>
      <phone>251-445-9649</phone>
      <email>rwrussell@health.southalabama.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer Scalici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marquis Simms</last_name>
      <phone>410-955-8849</phone>
      <email>msimms10@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Deery, RN</last_name>
      <phone>410-502-0669</phone>
      <email>ahorne1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deborah Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehan Ganachaud, M.Sc.</last_name>
      <phone>314-747-9202</phone>
      <email>ganachaud.j@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dave Schwab</last_name>
      <email>dschwab@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Schwarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Neagle, RN, BSN</last_name>
      <phone>980-442-2303</phone>
      <email>Heather.Neagle@Carolinashealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Parker</last_name>
      <email>Melissa.M.Parker@atriumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Crane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Braden Curry</last_name>
      <phone>405-271-8777</phone>
      <email>braden-curry@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>HeeSun Kim-Suh</last_name>
      <email>HeeSun-Kim@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Moxley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Clift</last_name>
      <phone>434-924-2745</phone>
      <email>SHC2WN@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Dukes</last_name>
      <phone>703-970-6554</phone>
      <email>Shelby.Dukes@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Vatannia</last_name>
      <phone>571.472.0623</phone>
      <email>Emily.Vatannia@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chad Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Loyall</last_name>
      <phone>804-628-2667</phone>
      <email>ployall@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nichole Calandrinno</last_name>
      <phone>804-628-2334</phone>
      <email>calandrinn@vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Emma Fields, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Linda R Duska</investigator_full_name>
    <investigator_title>Associate Professor, Division of Gynecology Oncology</investigator_title>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

